SGFG
TVTX icon

Silver Grove Financial Group’s Travere Therapeutics TVTX Stock Holding History

Silver Grove Financial Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.2K Buy
+74
New +$3.28K ﹤0.01% 1278

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silver Grove Financial Group's TVTX Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 74 shares worth $4.2K. The stake represents ﹤0.01% of the portfolio and ranks #1278 among its holdings.

319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Silver Grove Financial Group held 74 shares of Travere Therapeutics worth $4.2K as of Q2 2026.
  • Travere Therapeutics was a new Silver Grove Financial Group position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #1278 holding.
  • 319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.